ArticleCancer discovery2023
Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival?
Article in Cancer discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- TWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitors.Journal of experimental & clinical cancer research : CR · 2026Article
- Retroperitoneal Dedifferentiated Liposarcoma With Penetrating Abscess Formation Secondary to Ileal Invasion: A Case Report.Clinical case reports · 2026Article
- Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications.Cancers · 2024Review
- The molecular tumor board as a step in cancer patient management: a southern Italian experience.Frontiers in medicine · 2024Article
- Comparative Expression Analysis ofCancer diagnosis & prognosisArticle
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Murine double minute 2 (MDM2) inhibitors represent an opportunity to target p53 in solid tumors with wild-type TP53 and particularly in some sarcomas characterized by a consistent amplification of the MDM2 gene. In this issue of Cancer Discovery, LoRusso and colleagues and Koyama and colleagues report the results of two early-phase studies investigating two different TP53-MDM2 antagonists in patients with soft-tissue sarcomas and other solid tumors. See related article by LoRusso et al., p. 1802 (5) . See related article by Koyama et al., p. 1814 (8) .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.